These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17640780)

  • 21. Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
    Chou TH; Wang S; Sakhatskyy PV; Mboudjeka I; Lawrence JM; Huang S; Coley S; Yang B; Li J; Zhu Q; Lu S
    Virology; 2005 Mar; 334(1):134-43. PubMed ID: 15749129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.
    Hu H; Lu X; Tao L; Bai B; Zhang Z; Chen Y; Zheng F; Chen J; Chen Z; Wang H
    Clin Vaccine Immunol; 2007 Jul; 14(7):894-901. PubMed ID: 17494640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice.
    Qu D; Zheng B; Yao X; Guan Y; Yuan ZH; Zhong NS; Lu LW; Xie JP; Wen YM
    Vaccine; 2005 Jan; 23(7):924-31. PubMed ID: 15603894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.
    Zhang H; Wang G; Li J; Nie Y; Shi X; Lian G; Wang W; Yin X; Zhao Y; Qu X; Ding M; Deng H
    J Virol; 2004 Jul; 78(13):6938-45. PubMed ID: 15194770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.
    Du L; Zhao G; Chan CC; Sun S; Chen M; Liu Z; Guo H; He Y; Zhou Y; Zheng BJ; Jiang S
    Virology; 2009 Oct; 393(1):144-50. PubMed ID: 19683779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection.
    Li K; Li Z; Wohlford-Lenane C; Meyerholz DK; Channappanavar R; An D; Perlman S; McCray PB; He B
    mBio; 2020 Apr; 11(2):. PubMed ID: 32265331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection.
    Du L; Zhang X; Liu J; Jiang S
    J Vis Exp; 2011 May; (51):. PubMed ID: 21587153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS.
    Callendret B; Lorin V; Charneau P; Marianneau P; Contamin H; Betton JM; van der Werf S; Escriou N
    Virology; 2007 Jul; 363(2):288-302. PubMed ID: 17331558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies.
    Kuate S; Cinatl J; Doerr HW; Uberla K
    Virology; 2007 May; 362(1):26-37. PubMed ID: 17258782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome.
    Jiang S; Bottazzi ME; Du L; Lustigman S; Tseng CT; Curti E; Jones K; Zhan B; Hotez PJ
    Expert Rev Vaccines; 2012 Dec; 11(12):1405-13. PubMed ID: 23252385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector.
    Kapadia SU; Simon ID; Rose JK
    Virology; 2008 Jun; 376(1):165-72. PubMed ID: 18396306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants.
    Deming D; Sheahan T; Heise M; Yount B; Davis N; Sims A; Suthar M; Harkema J; Whitmore A; Pickles R; West A; Donaldson E; Curtis K; Johnston R; Baric R
    PLoS Med; 2006 Dec; 3(12):e525. PubMed ID: 17194199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses.
    Huang J; Cao Y; Du J; Bu X; Ma R; Wu C
    Vaccine; 2007 Sep; 25(39-40):6981-91. PubMed ID: 17709158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies.
    Zhou T; Wang H; Luo D; Rowe T; Wang Z; Hogan RJ; Qiu S; Bunzel RJ; Huang G; Mishra V; Voss TG; Kimberly R; Luo M
    J Virol; 2004 Jul; 78(13):7217-26. PubMed ID: 15194798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.
    Iwata-Yoshikawa N; Uda A; Suzuki T; Tsunetsugu-Yokota Y; Sato Y; Morikawa S; Tashiro M; Sata T; Hasegawa H; Nagata N
    J Virol; 2014 Aug; 88(15):8597-614. PubMed ID: 24850731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
    Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
    Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.
    Yi CE; Ba L; Zhang L; Ho DD; Chen Z
    J Virol; 2005 Sep; 79(18):11638-46. PubMed ID: 16140741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.
    Bukreyev A; Lamirande EW; Buchholz UJ; Vogel LN; Elkins WR; St Claire M; Murphy BR; Subbarao K; Collins PL
    Lancet; 2004 Jun; 363(9427):2122-7. PubMed ID: 15220033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV.
    Yasui F; Kai C; Kitabatake M; Inoue S; Yoneda M; Yokochi S; Kase R; Sekiguchi S; Morita K; Hishima T; Suzuki H; Karamatsu K; Yasutomi Y; Shida H; Kidokoro M; Mizuno K; Matsushima K; Kohara M
    J Immunol; 2008 Nov; 181(9):6337-48. PubMed ID: 18941225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses.
    Liniger M; Zuniga A; Tamin A; Azzouz-Morin TN; Knuchel M; Marty RR; Wiegand M; Weibel S; Kelvin D; Rota PA; Naim HY
    Vaccine; 2008 Apr; 26(17):2164-74. PubMed ID: 18346823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.